Signifor Lar

Monitor for adrenal insufficiency; give steroid replacement therapy if confirmed. Risk of hyperglycemia; initiate or adjust antidiabetic treatment if occurs; reduce Signifor LAR or discontinue if remains uncontrolled. Monitor HbA1c and FPG prior to initiation, weekly for first 3 months, 4–6 weeks after dose increase, and thereafter as indicated. Monitor for ketoacidosis; if suspected, discontinue and evaluate promptly. Congenital long QT prolongation. Cardiac disease (eg, recent MI, CHF, unstable angina, significant bradycardia); monitor QT interval at 21 days. High-grade heart block. Hypokalemia and/or hypomagnesemia; correct and monitor electrolytes prior to starting and during therapy. Monitor liver tests prior to initiation, 2–3 weeks after, then monthly for 3 months, then as indicated. Discontinue if significant hepatic impairment develops. Monitor baseline ECG, pituitary function prior to initiation and periodically during treatment. Discontinue and treat if cholelithiasis complications are suspected. Renal impairment: not studied. Premenopausal women: potential for unintended pregnancy due to improved fertility. Pregnancy. Nursing mothers.